Tagrix 80 mg is a specific branded pharmaceutical product containing osimertinib.
Product profile
| Product attribute | Information |
|---|---|
| Product | Tagrix 80 mg |
| Generic name | Osimertinib |
| Active substance | Osimertinib |
| Salt | Osimertinib mesylate |
| Strength | 80 mg |
| Dosage form | Film-coated tablet |
| Route | Oral |
| Drug class | EGFR tyrosine kinase inhibitor |
| Manufacturer | Beacon Pharmaceuticals Limited |
| Pack | 30 tablets / 3 × 10 Alu-Alu according to Beacon product information |
Therapeutic role
The active ingredient, osimertinib, is used in selected EGFR-mutated NSCLC treatment settings.
Reference product
TAGRISSO is the AstraZeneca reference product associated with osimertinib. Tagrix is a separate branded product.
Product verification
Product identity should be checked against current manufacturer documentation and legitimate supply channels.
Safety
Important risks include pulmonary toxicity, QTc prolongation, cardiomyopathy and ocular toxicity.